Bumex

AssetAlso called PF-1593, RO 10-6338, S-95008., Bumetanide

Stage: Approved
Modality: Not known
Target: SLC12A1; 1
Indication: 19
Trials: 1
Developer

Approved by the FDA on Feb 28, 1983 (NDA018225). 2 approvals stand. FDA

Indications

1

Edema associated with congestive heart failure
Approved, FDA

In the full profile

Target and mechanism2
Owner and partners1
Trials19
Evidence for its targets2
Competitors4
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.